Cutting-edge cellular therapies are redefining transplant and cancer treatment modalities. UCLA researchers engineered AlloCAR70-NKT, an off-the-shelf immunotherapy targeting metastatic kidney cancer with multi-pronged efficacy, circumventing traditional customization delays. Parallel research advances regulatory T cell and virus-specific T cell therapies to enhance graft survival and mitigate complications. Together, these innovations signal transformative potential in transplant immunotherapy.